1. Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results 
Becky Pennington, MSc, Sarah Davis, MPhys 
Value in Health 
Volume 17, Issue 8, Pages (December 2014)
DOI: /j.jval
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1
PRISMA diagram for MEDLINE search. BRAM, Birmingham Rheumatoid Arthritis Model; EQ-5D, EuroQol five-dimensional questionnaire; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Value in Health  , DOI: ( /j.jval )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
Incremental discounted quality-adjusted life-years (QALYs) compared with disease-modifying antirheumatic drugs (DMARDs). HAQ, Health Assessment Questionnaire.
Value in Health  , DOI: ( /j.jval )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

4. Fig. 3
Incremental cost-effectiveness ratios for rituximab versus disease-modifying antirheumatic drugs (DMARDs) and abatacept versus rituximab. HAQ, Health Assessment Questionnaire; QALY, quality-adjusted life-year.
Value in Health  , DOI: ( /j.jval )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

5. Fig. 4
Cost-effectiveness plane and cost-effectiveness efficiency frontiers produced from sensitivity analysis for the effect of each biologic on pain. QALY, quality-adjusted life-year.
Value in Health  , DOI: ( /j.jval )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions